CN110136845A - A kind of anti-tumor drug overall evaluation system - Google Patents
A kind of anti-tumor drug overall evaluation system Download PDFInfo
- Publication number
- CN110136845A CN110136845A CN201910436331.2A CN201910436331A CN110136845A CN 110136845 A CN110136845 A CN 110136845A CN 201910436331 A CN201910436331 A CN 201910436331A CN 110136845 A CN110136845 A CN 110136845A
- Authority
- CN
- China
- Prior art keywords
- index
- value
- module
- item
- evaluation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a kind of anti-tumor drug overall evaluation systems, including data memory module, for storing the detected value of collected each index item；Data screening module, the detected value for each index item needed for filtering out this evaluation from data memory module；Variable configuration module is used for according to preset variable allocation table, to the detected value distribution and computation value of each index item filtered out；Overall merit module, for the variable according to index total item and each index item, read group total obtains the comprehensive evaluation result of anti-tumor drug.System may be implemented to carry out anti-tumor drug overall merit through the invention, and improve the accuracy of evaluation result.
Description
Technical field
The present invention relates to field of medical technology, in particular to a kind of anti-tumor drug overall evaluation system.
Background technique
Although drug must be through stringent pharmacy, non-clinical and clinical research, since sample size is limited, grinds before listing
Study carefully the reasons such as the period is short, is also not enough to situations such as finding toxicity at a specified future date, therefore, behind marketing drugs, the lasting tracking of drug is commented
Valence seems extremely important.Existing drug assessment technology such as Methods of Health Technology Assessment (health technology assessment,
It HTA) can be to clinical safety, validity (efficiency, effect and life quality), Economics Characteristics (cost-effectiveness, cost-effect
Benefit, cost-effectiveness) and the comprehensive and systematic evaluation of social adaptiveness's progress, but still certain limitation is deposited, and as: 1) HTA completes week
Phase is longer, can not adapt to oncotherapy progress and update rapid situation；2) lack objective appraisal system and give quantitative analysis, it can
Energy can be because of index omission or index value misregistration etc. caused by implementation personnel's difference, so that final appraisal results inaccuracy and efficiency
It is lower.
Summary of the invention
The object of the present invention is to provide a kind of anti-tumor drug overall evaluation system, evaluative dimension is comprehensive, transparent, guiding is clear
Chu, emphasis be clear, strong operability is, it can be achieved that objectively to the objective overall merit of anti-tumor drug, and it is quasi- to improve evaluation result
True property.
For this purpose, the embodiment of the invention provides a kind of anti-tumor drug overall evaluation systems, comprising:
Data memory module, for storing the detected value of collected each index item；
Data screening module, data input pin connect the data output end of data memory module, for storing from data
The detected value of each index item needed for filtering out this evaluation in module；
Variable configuration module, data input pin connect the data output end of data screening module, and variable configures mould
Block is used for according to preset variable allocation table, to the detected value distribution and computation value of each index item filtered out；
Overall merit module, data input pin connect the data output end of variable configuration module, overall merit module
For the weight according to the variable of index total item and each index item, each index item, read group total obtains anti-tumor drug
Comprehensive evaluation result.As a result score it is higher represent the drug or therapeutic scheme value it is higher.
It according to embodiments of the present invention, include multinomial first class index in evaluation index model, each first class index is by multinomial two
Grade index is constituted, each two-level index is made of one or more three-level indexs；The data screening module is specifically used for screening
The detected value of each three-level index item needed for this evaluation out；
The overall merit module includes the first operation submodule, the second operation submodule and third operation submodule, the
One operation submodule obtains a two-level index according to the item number of three-level index and the variable of each three-level index item, read group total
Comprehensive evaluation value, the second operation submodule is according to the item number of two-level index and the comprehensive evaluation value of each two-level index item, summation
It is calculated the comprehensive evaluation value of a first class index, third operation submodule is according to the item number and each first class index of first class index
The comprehensive evaluation value of item, read group total obtain the comprehensive evaluation result of anti-tumor drug.In the present embodiment, overall merit module
Using three layers of calculating structure, it can be used for the evaluation of three-level index, the setting of three-level index refines evaluation analysis process more, more
With specific aim and reliability.
In more optimized scheme, above-mentioned anti-tumor drug overall evaluation system further includes drawing module, for according to anti-
The comprehensive evaluation result of tumour medicine draws radar map, illustrates the comprehensive evaluation value of every first class index in the radar map.
By drawing radar map, it can more intuitively show comprehensive evaluation result, conveniently check.
As an implementation, the first class index include Disease Spectrum, therapeutic value, drug research and development value, it is described
The two-level index that Disease Spectrum includes has individual burden, family burden, burden on society, the two-level index that the therapeutic value includes
There are adverse reaction, value of survival, an economic factor, the two-level index that the drug research and development value includes has innovative value, alternative.
These indexs are that have very high reliability based on obtained by Delphi Experts consultation method statistical analysis.
Compared with prior art, the objectively overall merit to anti-tumor drug may be implemented in system through the invention, no
By analysis personnel's subjective impact, evaluation result will not be caused inaccurate because index is omitted, it is comprehensive that drug can be improved
The accuracy for closing evaluation result, in addition can also be improved analysis efficiency.This evaluation system is comprehensive, transparent, guiding is clear, emphasis is bright
Really, strong operability, the accuracy based on evaluation result is high, can provide technical support for clinical practice, doctor patient communication, is real
Present price value medical target, it is ensured that the scientific and reasonable balance of medical resource provides data and supports, is conducive to indicate anti-tumor drug
Research direction and reduction drug research cost input.Anti-tumor drug value assessment can be intuitively shown by the drafting of radar map
As a result.
The weight of items three-level index of the invention is statisticallyd analyze based on Delphi Experts consultation method, and each valence is represented
Being worth evaluative dimension influences the importance of comprehensive evaluation result, improves external existing value assessment tool without caused by weight distribution
Comprehensive evaluation result is not easily distinguishable the limitation of superiority and inferiority, increases result sensibility, the transparency and science.In addition, being integrally formed
Comprehensive evaluation result shown with score, it is objective directly, different pharmaceutical and therapeutic scheme value can be distinguished, overcome external existing
Value assessment tool, which is not integrated value assessment result and shown with text, is not easy the puzzlement that is easily absorbed on a cognitive level by the user, convenient for result interpret with
Recommend, there is stronger scientific, practicability and operability.The system also can be other countries/area value assessment reference.
Detailed description of the invention
In order to illustrate the technical solution of the embodiments of the present invention more clearly, below will be to needed in the embodiment attached
Figure is briefly described, it should be understood that the following drawings illustrates only certain embodiments of the present invention, therefore is not construed as pair
The restriction of range for those of ordinary skill in the art without creative efforts, can also be according to this
A little attached drawings obtain other relevant attached drawings.
Fig. 1 is the structural schematic block diagram of anti-tumor drug overall evaluation system described in the present embodiment.
Fig. 2 is the radar map of comprehensive evaluation result described in the present embodiment.
Specific embodiment
Below in conjunction with attached drawing in the embodiment of the present invention, technical solution in the embodiment of the present invention carries out clear, complete
Ground description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Usually exist
The component of the embodiment of the present invention described and illustrated in attached drawing can be arranged and be designed with a variety of different configurations herein.Cause
This, is not intended to limit claimed invention to the detailed description of the embodiment of the present invention provided in the accompanying drawings below
Range, but it is merely representative of selected embodiment of the invention.Based on the embodiment of the present invention, those skilled in the art are not doing
Every other embodiment obtained under the premise of creative work out, shall fall within the protection scope of the present invention.
Referring to Fig. 1, present embodiments providing a kind of anti-tumor drug overall evaluation system, comprising: data memory module,
Data screening module, variable configuration module, synthesis result evaluation module and drawing module.Wherein,
Data memory module is used to store the detected value of collected each index item.
The data output end of the data input pin connection data memory module of data screening module, for storing mould from data
The detected value of each index item needed for filtering out this evaluation in block.Generally, the data of acquisition are in contrast relatively more comprehensive, and
Based on different application demands, it is possible to it is different to the selection of evaluation index, in the present embodiment, by the way that data screening mould is arranged
The screening of data may be implemented in block, to adapt to different evaluation requirements, enhances the applicability of this system.The module overcomes existing
Drug value appraisal tool can not evaluate the limitation using nonrandomized controlled test as source of evidence, make supplemented with observational study
For adverse reaction evaluation important evidence source, widened applicability, preferably solve " real world study evidence be antitumor
This realistic problem of the important sources of medication medication treatment clinical practice ", advantage are definite.
The data output end of the data input pin connection data screening module of variable configuration module, variable configuration module
For according to variable allocation table, to the detected value distribution and computation value of each index item filtered out.Detected value is matched by variable
After setting module configuration variable, the product of the combining weights of gained variable and respective items three-level index is this three-level index
Final result value.Generally, the project for the evaluation index of anti-tumor drug is more, the data of different types of index item
It is also inconsistent to be worth representation, as shown in table 1, therefore, by the way that variable configuration module is arranged, the detected value of indices is used
The variable of unified expression indicates, carries out operation convenient for overall merit module, also avoids leading because of different data expression way
Calculated result inaccuracy is caused, and then ensures the accuracy of final comprehensive evaluation result.
The data output end of the data input pin connection variable configuration module of overall merit module, overall merit module are used
In the variable according to index total item and each index item, read group total obtains the comprehensive evaluation result of anti-tumor drug.
It as an implementation, may include multinomial first class index in evaluation index model, each first class index is by more
Item two-level index is constituted, each two-level index is made of one or more three-level indexs.As an example, the first class index includes
Disease Spectrum, therapeutic value, drug research and development value, the two-level index that the Disease Spectrum includes have individual burden, family burden,
Burden on society, the effective in cure value of the two-level index that the therapeutic value includes, adverse reaction, value of survival, economic factor are described
The two-level index that drug research and development value includes has innovative value, alternative；First class index can also include source of evidence and class
Type, evidence recommendation grade, the evidence degree of homogenization, value result composition/integration, public's feedback and comment, wherein the evidence
The two-level index that source and type include has secondary research, real world research, and the second level that the evidence recommendation grade includes refers to
Indicate evaluation of evidential matter tool, evaluation of evidential matter target, the two-level index that the evidence degree of homogenization includes homogeney, card on evidence
According to updating or correcting, the two-level index that value result composition/integration includes has result weight, result formats, and public's feedback includes
Two-level index have public's feedback mechanism, the public feed back the frequency.As shown in table 1.
Table 1
Based on evaluation index model shown in table 1, the structure of the overall merit module includes the first operation submodule, the
Two operation submodules and third operation submodule, the first operation submodule is according to the item number of three-level index and each three-level index item
Variable, read group total obtain the comprehensive evaluation value of a two-level index, and the second operation submodule is according to the item number of two-level index
And the comprehensive evaluation value of each two-level index item, read group total obtain the comprehensive evaluation value of a first class index, third operation submodule
Root tuber is commented according to the item number of first class index and the comprehensive evaluation value of each first class index item, the synthesis that read group total obtains anti-tumor drug
Valence result.Readily comprehensible, based on different index classifications, the structure of overall merit module is also different, right in the present embodiment
This does not do particular determination, above-mentioned to illustrate only as one.
As an example, the detected value of every three-level index and the variable of distribution are as shown in table 2.
Table 2
In above-mentioned table 2, combining weights are the final weight of three-level index, and combining weights are based on Delphi expert consulting
Obtained by method statistical analysis, bottom three-level index valuation scheme is also based on Delphi Experts consultation method and reaches common understanding, and simultaneously
Non- random setting, therefore there is very high reliability.The detected value of one three-level index is by variable configuration module configuration meter
After magnitude, the product of gained variable and combining weights is the final result value of this three-level index, multinomial three-level index
The summation of final result value obtains the final result value an of two-level index, and the final result value of multinomial two-level index is summed to obtain the final product
To the final result value of a first class index.
It further include drawing module in above-mentioned anti-tumor drug overall evaluation system, data input pin connects overall merit mould
The data output end of block, drawing module are used to draw radar map according to comprehensive evaluation result, illustrate every level-one in radar map
The comprehensive evaluation value of index, as shown in Figure 2.By drawing radar map, the more preferable displaying of comprehensive evaluation result may be implemented, conveniently
It checks.Certain applications are directed to, such as need to highlight certain index item paid close attention to, this overall evaluation system can be with
Including mark module, it is marked for the comprehensive evaluation value to the first class index specified in radar map to realize and highlight.
Real example citing
By taking bevacizumab, Mycocet are respectively used to platinum responsive type recurrent ovarian carcinoma as an example, its value is compared,
As shown in table 3.
Table 3
| Serial number | Drug target | Evaluation group scheme | Control group scheme | It is worth total score |
| 1 | Bevacizumab | Bevacizumab+gemcitabine+carboplatin | Gemcitabine+carboplatin | |
| 2 | Mycocet | Mycocet+carboplatin | Taxol+carboplatin |
Value assessment Comparative result is as shown in table 4.
Table 4
Wherein, the radar map of bevacizumab+gemcitabine+Carboplatin in patients Drug-resistant Recurrent type oophoroma comprehensive evaluation result
As shown in Figure 2.
System may be implemented that evaluation result is served clinic to the value overall merit of anti-tumor drug through the invention
It practices, doctor patient communication offer technical support, is realized value medical target, it is ensured that the scientific and reasonable balance offer of medical resource is determined
Plan opinion and suggestion are conducive to the research direction for indicating anti-tumor drug and reduce drug research cost input.Pass through radar map
Drafting can intuitively show anti-tumor drug value assessment result.
In addition, in the above-described embodiments, be related to specific targets 56, cover 8 aspects such as therapeutic value, evaluative dimension compared with
The existing drug value appraisal tool in the whole world is wide；Overcoming existing drug value appraisal tool can not evaluate with nonrandomized controlled test
It has widened and has been applicable in supplemented with the important evidence source that observational study is evaluated as adverse reaction for the limitation of source of evidence
Property, preferably solve " important sources that real world research evidence is the practice of anti-tumor drug drug therapy clinical " this reality
Problem, advantage are definite；It is assessed based on value-orientation, sensibility is high, can distinguish different pharmaceutical and therapeutic scheme value, be convenient for result
It interprets and recommends；The system also can be other countries/area value assessment reference.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those familiar with the art in the technical scope disclosed by the present invention, can easily think of the change or the replacement, and should all contain
Lid is within protection scope of the present invention.
Claims (5)
1. a kind of anti-tumor drug overall evaluation system characterized by comprising
Data memory module, for storing the detected value of collected each index item；
Data screening module, data input pin connect the data output end of data memory module, are used for from data memory module
In filter out this evaluation needed for each index item detected value；
Variable configuration module, data input pin connect the data output end of data screening module, and variable configuration module is used
According to preset variable allocation table, to the detected value distribution and computation value of each index item filtered out；
Overall merit module, data input pin connect the data output end of variable configuration module, and overall merit module is used for
According to the weight of the variable of index total item and each index item, indices, read group total obtains the synthesis of anti-tumor drug
Evaluation result.
2. system according to claim 1, which is characterized in that it include multinomial first class index in evaluation index model, each
First class index is made of multinomial two-level index, each two-level index is made of one or more three-level indexs；The data screening
Module is specifically used for the detected value of each three-level index item needed for filtering out this evaluation；
The overall merit module includes the first operation submodule, the second operation submodule and third operation submodule, the first fortune
Operator module obtains the comprehensive of a two-level index according to the item number of three-level index and the variable of each three-level index item, read group total
Evaluation of estimate is closed, the second operation submodule is according to the item number of two-level index and the comprehensive evaluation value of each two-level index item, read group total
Obtain the comprehensive evaluation value of a first class index, third operation submodule is according to the item number of first class index and each first class index item
Comprehensive evaluation value, read group total obtain the comprehensive evaluation result of anti-tumor drug.
3. system according to claim 2, which is characterized in that further include drawing module, for according to anti-tumor drug
Comprehensive evaluation result draws radar map, illustrates the comprehensive evaluation value of every first class index in the radar map.
4. system according to claim 3, which is characterized in that further include mark module, for in radar map specify
The comprehensive evaluation value of first class index is marked to realize and highlight.
5. system according to claim 2, which is characterized in that the first class index includes Disease Spectrum, therapeutic value, medicine
Product research and development value, the two-level index that the Disease Spectrum includes have individual burden, family burden, burden on society, the treatment valence
The two-level index that value includes has adverse reaction, value of survival, economic factor, and the two-level index that the drug research and development value includes has
It is innovative value, alternative.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910436331.2A CN110136845A (en) | 2019-05-23 | 2019-05-23 | A kind of anti-tumor drug overall evaluation system |
| PCT/CN2019/090335 WO2020232757A1 (en) | 2019-05-23 | 2019-06-06 | Antitumor drug comprehensive evaluation system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910436331.2A CN110136845A (en) | 2019-05-23 | 2019-05-23 | A kind of anti-tumor drug overall evaluation system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110136845A true CN110136845A (en) | 2019-08-16 |
Family
ID=67573043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910436331.2A Pending CN110136845A (en) | 2019-05-23 | 2019-05-23 | A kind of anti-tumor drug overall evaluation system |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110136845A (en) |
| WO (1) | WO2020232757A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111785395A (en) * | 2020-05-08 | 2020-10-16 | 四川大学华西第二医院 | Monitoring method, system, equipment and storage medium for clinical application of antibacterial drugs |
| CN113488132A (en) * | 2021-06-16 | 2021-10-08 | 中南大学湘雅医院 | System for controlling risk of drug shortage |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165762A1 (en) * | 2001-05-02 | 2002-11-07 | Clinical Discovery Israel Ltd. | Method for integrated analysis of safety, efficacy and business aspects of drugs undergoing development |
| CN104636587A (en) * | 2013-11-11 | 2015-05-20 | 邢蓉 | Drug utilization and evaluation method based on weighted TOPSIS method |
| CN107256426A (en) * | 2017-06-19 | 2017-10-17 | 湖北省食品药品监督检验研究院 | A kind of drug safety confidence index system and construction method based on intelligent algorithm |
| CN107480443A (en) * | 2017-08-08 | 2017-12-15 | 复旦大学附属儿科医院 | A kind of clinical drug integrated evaluating method based on real world |
| CN109559831A (en) * | 2018-10-26 | 2019-04-02 | 山东省立医院 | A kind of method for estimating curative effect based on anticancer drug clinical laboratory data |
-
2019
- 2019-05-23 CN CN201910436331.2A patent/CN110136845A/en active Pending
- 2019-06-06 WO PCT/CN2019/090335 patent/WO2020232757A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165762A1 (en) * | 2001-05-02 | 2002-11-07 | Clinical Discovery Israel Ltd. | Method for integrated analysis of safety, efficacy and business aspects of drugs undergoing development |
| CN104636587A (en) * | 2013-11-11 | 2015-05-20 | 邢蓉 | Drug utilization and evaluation method based on weighted TOPSIS method |
| CN107256426A (en) * | 2017-06-19 | 2017-10-17 | 湖北省食品药品监督检验研究院 | A kind of drug safety confidence index system and construction method based on intelligent algorithm |
| CN107480443A (en) * | 2017-08-08 | 2017-12-15 | 复旦大学附属儿科医院 | A kind of clinical drug integrated evaluating method based on real world |
| CN109559831A (en) * | 2018-10-26 | 2019-04-02 | 山东省立医院 | A kind of method for estimating curative effect based on anticancer drug clinical laboratory data |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111785395A (en) * | 2020-05-08 | 2020-10-16 | 四川大学华西第二医院 | Monitoring method, system, equipment and storage medium for clinical application of antibacterial drugs |
| CN113488132A (en) * | 2021-06-16 | 2021-10-08 | 中南大学湘雅医院 | System for controlling risk of drug shortage |
| CN113488132B (en) * | 2021-06-16 | 2023-03-14 | 中南大学湘雅医院 | System for controlling risk of drug shortage |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020232757A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stoumpos et al. | Digital transformation in healthcare: technology acceptance and its applications | |
| Nelson | Systematic reviews to answer health care questions | |
| Puvanachandra et al. | Burden of road traffic injuries in Turkey | |
| Santacroce et al. | A systematic scoping review of the recent literature (∼ 2011–2017) about the costs of illness to parents of children diagnosed with cancer | |
| CN101421734A (en) | System and method for identifying and analyzing patterns or aberrations in healthcare claims | |
| CN110136845A (en) | A kind of anti-tumor drug overall evaluation system | |
| Chambers et al. | The impact of big data research on practice, policy, and cancer care | |
| Zhou et al. | Primary care quality and cost for privately insured patients in and out of US Health Systems: Evidence from four states | |
| Bell et al. | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia | |
| De Souza et al. | Data envelopment analysis of efficiency in hospital organisations | |
| Díez-Fernández et al. | Flash glucose monitoring and patient satisfaction: a meta-review of systematic reviews | |
| Ille et al. | Non-invasive mapping for effective preoperative guidance to approach highly language-eloquent gliomas—a large scale comparative cohort study using a new classification for language eloquence | |
| Faria et al. | The economics of medicines optimization: policy developments, remaining challenges and research priorities | |
| Bethell et al. | Social integration and loneliness among long-term care home residents: protocol for a scoping review | |
| Daley et al. | Use of electroneuromyography in the diagnosis of neurogenic thoracic outlet syndrome: a systematic review and meta-analysis | |
| Afzali et al. | A conceptual framework for selecting the most appropriate variables for measuring hospital efficiency with a focus on Iranian public hospitals | |
| Orkin et al. | Defining and measuring health equity effects in research on task shifting interventions in high-income countries: a systematic review protocol | |
| Taylor et al. | An all-inclusive and transparent view of a vascular program's direct impact on its health system | |
| Scarlat et al. | Equal access to orthopaedic research funding, databases and scientific publications | |
| Yazdanian et al. | A review of oncology clinical information systems-what are the critical success factors and reasons for system failure | |
| de Oliveira et al. | Long-term outcomes in severe traumatic brain injury and associated factors: a prospective cohort study | |
| Esposito et al. | Clinical network for big data and personalized health: study protocol and preliminary results | |
| Egger et al. | Postoperative Femoral Nerve Palsy and Meralgia Paresthetica after Gynecologic Oncologic Surgery | |
| Quigley et al. | Regional health organisations: An evidence review | |
| Weingart et al. | Bibliometric indicators for assessing strengths and weaknesses of West German science |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |